Journal Watch · PLOS Biology · 2026

Disrupting CD22-cis-ligand interactions ameliorates type 1 diabetes and graft rejection by expanding regulatory B cells.

Treatment of mice with 1C5 ameliorates skin graft rejection and type 1 diabetes with expansion of regulatory γδ T cells probably through expansion of Breg cells, suggesting ligand interaction of CD22 as a novel target of therapy for autoimmune diseases and graft rejection.

Long W, Endo A, Walakulu Gamage HN et al.PLOS Biology3 min readPharma relevance 60/100

DOI: 10.1371/journal.pbio.3003681PMID: 41875099Study type: preclinical (animal / model) study

TL;DR

Treatment of mice with 1C5 ameliorates skin graft rejection and type 1 diabetes with expansion of regulatory γδ T cells probably through expansion of Breg cells, suggesting ligand interaction of CD22 as a novel target of therapy for autoimmune diseases and graft rejection.

Key findings

  • CD22 appears to recognize BCR and TLRs thereby directly or indirectly suppressing TLR signaling essential for expansion of Breg cells.
  • Treatment of mice with 1C5 ameliorates skin graft rejection and type 1 diabetes with expansion of regulatory γδ T cells probably through expansion of Breg cells, suggesting ligand interaction of CD22 as a novel target of therapy for autoimmune diseases and graft rejection.

What they did

To address the role of ligand interaction of CD22 in immune responses, here we generated anti-CD22 antibody 1C5 that specifically inhibits ligand binding of CD22. Both Cd22-/- mice and mice treated with 1C5 show expansion of regulatory B (Breg) cells in follicular (FO) B cells, suggesting a crucial role of ligand interaction of CD22 in inhibiting the expansion of FO Breg cells.

Full abstract (original)

Background: CD22 is an inhibitory receptor expressed in B cells and is constitutively associated with α2,6-sialylated membrane proteins expressed on the same cell (cis-ligands). However, interaction with cis-ligands is required for the function of CD22 only in part.

What they did: To address the role of ligand interaction of CD22 in immune responses, here we generated anti-CD22 antibody 1C5 that specifically inhibits ligand binding of CD22. Both Cd22-/- mice and mice treated with 1C5 show expansion of regulatory B (Breg) cells in follicular (FO) B cells, suggesting a crucial role of ligand interaction of CD22 in inhibiting the expansion of FO Breg cells.

Results & conclusions: CD22 appears to recognize BCR and TLRs thereby directly or indirectly suppressing TLR signaling essential for expansion of Breg cells. Treatment of mice with 1C5 ameliorates skin graft rejection and type 1 diabetes with expansion of regulatory γδ T cells probably through expansion of Breg cells, suggesting ligand interaction of CD22 as a novel target of therapy for autoimmune diseases and graft rejection.

Abstract © the authors / PLOS Biology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1371/journal.pbio.3003681 · PubMed 41875099.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this PLOS Biology study find?

Treatment of mice with 1C5 ameliorates skin graft rejection and type 1 diabetes with expansion of regulatory γδ T cells probably through expansion of Breg cells, suggesting ligand interaction of CD22 as a novel target of therapy for autoimmune diseases and graft rejection.

What type of study is this?

It is a preclinical (animal / model) study, published in PLOS Biology in 2026. To address the role of ligand interaction of CD22 in immune responses, here we generated anti-CD22 antibody 1C5 that specifically inhibits ligand binding of CD22.

Where can I read the original paper?

The original is at the publisher via DOI 10.1371/journal.pbio.3003681. PubMed ID: 41875099. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Long W, Endo A, Walakulu Gamage HN et al.. Disrupting CD22-cis-ligand interactions ameliorates type 1 diabetes and graft rejection by expanding regulatory B cells.. PLOS Biology (2026). DOI: 10.1371/journal.pbio.3003681.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/disrupting-cd22-cis-ligand-interactions-ameliorates-type-1-diabetes-and-003681/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides